Bafna Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Operating margins have improved to 3.5% from -7.0%
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.13x)
- Company generates healthy free cash flow
CONS
- Company is loss-making at the operating / net level
- Company has a low return on equity of -45.8% over last 3 years
- Operating cash flow has been negative in recent years
- Company has a low return on capital employed of -10.7%
- Interest coverage is weak at -18.7x - earnings barely cover interest
- Promoter holding has decreased over last 2 years: -13.3pp
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BAFNAPH | 303.00 | 92.04 | 716.79 | 0.00 | 6.04 | — | 131.33 | — | 11.87 | 32.32 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | |
|---|---|
| 131 | |
| 94 | |
| Operating Profit | 37 |
| OPM % | 28.13% |
| 2 | |
| Interest | 0 |
| Depreciation | 5 |
| Profit before Tax | 22 |
| Tax % | 72.32% |
| Net Profit | 6 |
| 0.20 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|
| 129 | 176 | 185 | 139 | 85 | 65 | 47 | 44 | 42 | |
| 110 | 153 | 162 | 115 | 85 | 71 | 82 | 57 | 41 | |
| Operating Profit | 19 | 22 | 23 | 23 | 1 | -6 | -35 | -13 | 1 |
| OPM % | 14.50% | 12.79% | 12.33% | 16.90% | 0.61% | -8.94% | -74.48% | -29.97% | 2.88% |
| 1 | 3 | 2 | 2 | 2 | 1 | 31 | 0 | 0 | |
| Interest | 8 | 12 | 13 | 13 | 13 | 11 | 7 | 2 | 0 |
| Depreciation | 6 | 8 | 9 | 6 | 5 | 4 | 4 | 3 | 3 |
| Profit before Tax | 5 | 5 | 2 | 6 | -15 | -20 | -15 | -18 | -2 |
| Tax % | 64.53% | 26.93% | 42.02% | -2.51% | 1.16% | 4.43% | -14.90% | -5.84% | -0.00% |
| Net Profit | 2 | 4 | 1 | 6 | -15 | -19 | -17 | -19 | -2 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout % | 0.00% | 28.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- -21%
- 3 Years:
- -13%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- 19%
- 3 Years:
- 48%
- 1 Year:
- 170%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- -40%
- 3 Years:
- -46%
- Last Year:
- -25%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 19 | 19 | 19 | 19 | 19 | 24 | 24 | 2 |
| Minority Interest | 1 | 1 | 1 | 1 | -0 | -1 | -1 | -0 | 0 |
| 40 | 46 | 50 | 53 | 39 | 20 | 14 | -5 | -7 | |
| 86 | 101 | 110 | 69 | 81 | 95 | 59 | 47 | 3 | |
| Trade Payables | 58 | 79 | 42 | 42 | 38 | 24 | 29 | 40 | 13 |
| 15 | 15 | 15 | 16 | 16 | 21 | 13 | 14 | 60 | |
| Total Liabilities | 219 | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
| 76 | 73 | 69 | 55 | 53 | 49 | 45 | 37 | 35 | |
| 0 | 0 | 0 | 17 | 17 | 17 | 0 | 0 | 0 | |
| 24 | 22 | 27 | 16 | 16 | 17 | 11 | 9 | 11 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Bank | 2 | 21 | 3 | 3 | 3 | 3 | 3 | 3 | 8 |
| 116 | 144 | 136 | 109 | 104 | 93 | 80 | 70 | 16 | |
| Total Assets | 219 | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|
| 30 | 38 | 2 | 13 | 1 | -1 | -7 | -2 | -34 | |
| Cash from Investing | -38 | -6 | -7 | 60 | -0 | -5 | 38 | 15 | 33 |
| Cash from Financing | -1 | -12 | -13 | -71 | -1 | 6 | -31 | -14 | 7 |
| -9 | 19 | -18 | -0 | -0 | -0 | 0 | -0 | 6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-11 - Bafna Pharmaceuticals Limited has submitted to the Exchange Voting Results of the 31st Annual General Meeting of the Company held on September 11, 2026 along with the Scrutinizer Report.
2026-09-11 - Bafna Pharmaceuticals Limited has informed the Exchange regarding Proceedings of the 31st Annual General Meeting of the Company held on September 11, 2026
2026-08-21 - Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for the 31st Annual General Meeting of the Company published in ''Business Standard'' and ''Makkal Kural'' on August 20, 2026
2026-08-19 - Bafna Pharmaceuticals Limited has informed the Exchange regarding Notice of 31st Annual General Meeting of the Company to be held on September 11, 2026 along with the Annual Report for F.Y 2025-2026
2026-08-14 - Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on August 13, 2026
2026-08-13 - Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Intimation for Book Closure & Cut off Date'.
2026-08-13 - Bafna Pharmaceuticals Limited has informed the Exchange regarding intimation for 31st Annual General Meeting of the Company to be held on September 11, 2026
2026-08-11 - Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 11, 2026.
2026-08-11 - Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on 11/08/2026 along with the unaudited financial results for the quarter ended June 30, 2026.
News
Recent coverage and analyst commentary for BAFNAPH
Loading news…
AI Stock Analyst
Bafna Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account